KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer

Abiraterone, a novel androgen synthesis inhibitor, has been approved for castration-resistant prostate cancer (CRPC) treatment. However, most patients eventually acquire resistance to this agent, and the underlying mechanisms related to this resistance remain largely unelucidated. Lysine acetyltrans...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Dingheng, Song, Yarong, Yu, Ying, Wang, Decai, Liu, Bing, Chen, Liang, Li, Xuexiang, Li, Yunxue, Cheng, Lulin, Lv, Fang, Zhang, Pu, Xing, Yifei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357915/
https://www.ncbi.nlm.nih.gov/pubmed/34381019
http://dx.doi.org/10.1038/s41419-021-04077-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357915/
https://www.ncbi.nlm.nih.gov/pubmed/34381019
http://dx.doi.org/10.1038/s41419-021-04077-w

Ejemplares similares